Reaction: Levomilnacipran to 1 product

Reaction
Levomilnacipran
DB08918
    p-Hydroxy-levomilnacipran
    DBMET03703
    Reaction type
    hydroxylation
    Direction
    Major circulating metabolite?
    No
    Spontaneous?
    No
    Activity
    inactive
    References
    1. Brunner V, Maynadier B, Chen L, Roques L, Hude I, Seguier S, Barthe L, Hermann P: Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats. Drug Des Devel Ther. 2015 Jun 23;9:3199-215. doi: 10.2147/DDDT.S80886. eCollection 2015. [Article]
    2. Bruno A, Morabito P, Spina E, Muscatello MR: The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review. Curr Neuropharmacol. 2016;14(2):191-9. [Article]
    3. FDA Approved Drug Products: FETZIMA (levomilnacipran) extended-release capsules, for oral use (August 2023) [Link]
    Comments
    Not Available
    Enzymes
    Not Available